If You Invested in Inhibrx Biosciences Inc (INBX)

Inhibrx Biosciences, Inc. (NASDAQ: INBX) is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The company states that it utilizes diverse methods of protein engineering, including proprietary protein engineering platforms, to address the specific requirements of complex target and disease biology. Inhibrx Biosciences operates in the biological product manufacturing space and emphasizes therapies for oncology and, as described in several company disclosures, rare diseases.

According to multiple company press releases and SEC filings, Inhibrx Biosciences was incorporated in January 2024 as a direct, wholly owned subsidiary of Inhibrx, Inc. Prior to the sale of Inhibrx, Inc. and the INBRX‑101 program to Sanofi S.A., Inhibrx Biosciences acquired certain corporate infrastructure and other assets and liabilities through a series of internal restructuring transactions. Inhibrx, Inc. also completed a distribution to holders of its common stock of 92% of the issued and outstanding shares of Inhibrx Biosciences. Following these transactions, Inhibrx Biosciences became an independent, publicly traded entity with its own clinical pipeline.

Business focus and clinical pipeline

The company describes itself as having a pipeline of novel biologic therapeutic candidates built using multivalent formats, where the precise valency can be optimized in a target-centric way to mediate what it believes to be the most appropriate agonist function. Across its public disclosures, Inhibrx Biosciences consistently identifies two core clinical programs:

• Ozekibart (INBRX‑109) – a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody designed to exploit tumor‑biased cell death induced by DR5 activation. Ozekibart has been studied as a single agent and in combination regimens in several solid tumor indications, including advanced or metastatic, unresectable conventional chondrosarcoma, colorectal cancer, and Ewing sarcoma. Company communications note that ozekibart is being evaluated in a randomized, placebo‑controlled registrational trial in chondrosarcoma and in Phase 1/2 expansion cohorts in colorectal cancer and Ewing sarcoma.
• INBRX‑106 – a precisely engineered hexavalent single-domain antibody (sdAb)–based therapeutic candidate targeting OX40, described by the company as designed to be an optimized agonist of this co‑stimulatory receptor. It is being investigated in combination with pembrolizumab (Keytruda) in patients with locally advanced or metastatic solid tumors, including head and neck squamous cell carcinoma (HNSCC) and non‑small cell lung cancer (NSCLC), in Phase 1/2 and Phase 2/3 clinical settings.

Inhibrx Biosciences’ public statements emphasize that both ozekibart and INBRX‑106 utilize multivalent formats intended to allow precise control over valency in a target‑centric manner. This design approach is presented by the company as central to its protein engineering strategy and as a unifying feature of its current pipeline.

Oncology and rare disease orientation

Inhibrx Biosciences repeatedly describes its focus as developing therapeutics for oncology and, in some disclosures, oncology and rare diseases. The indications highlighted in its communications include:

• Unresectable or metastatic conventional chondrosarcoma
• Advanced or metastatic, unresectable colorectal cancer
• Advanced or metastatic, unresectable, relapsed, or refractory Ewing sarcoma
• Locally advanced unresectable or metastatic head and neck squamous cell carcinoma
• Checkpoint inhibitor refractory or relapsed non‑small cell lung cancer

The company notes that these settings often involve heavily pretreated or difficult‑to‑treat patient populations and describes unmet medical need in several of these tumor types. Inhibrx Biosciences also discloses that the U.S. Food and Drug Administration granted Fast Track designation to ozekibart for metastatic or unresectable conventional chondrosarcoma and orphan drug designation for chondrosarcoma.

Corporate history and structure

Inhibrx Biosciences’ origin is closely tied to a corporate restructuring of Inhibrx, Inc. The company reports that:

• It was incorporated in January 2024 as a direct, wholly owned subsidiary of Inhibrx, Inc.
• Prior to the sale of the INBRX‑101 program to Sanofi S.A., it acquired corporate infrastructure and other assets and liabilities from Inhibrx, Inc. through internal restructuring transactions.
• Inhibrx, Inc. completed a distribution to its shareholders of 92% of the issued and outstanding shares of Inhibrx Biosciences, resulting in Inhibrx Biosciences becoming a separately traded company.

Across its press releases and SEC filings, the company refers to itself as an emerging growth company and a clinical‑stage biopharmaceutical company, with its financial reporting reflecting the spin‑off and the earlier operations of the former parent.

Regulatory and clinical development disclosures

Inhibrx Biosciences uses its SEC filings and press releases to describe the status of its clinical programs and regulatory interactions. For ozekibart, the company has publicly discussed:

• A randomized, blinded, placebo‑controlled registrational trial in metastatic, unresectable conventional chondrosarcoma, with progression‑free survival as the primary endpoint and additional secondary endpoints such as overall survival, objective response rate, duration of response, disease control rate, quality of life, safety, pharmacokinetics, and anti‑drug antibodies.
• Expansion cohorts in colorectal cancer in combination with FOLFIRI, and in Ewing sarcoma in combination with irinotecan and temozolomide, including interim efficacy and safety observations.
• Plans, as described in company communications, to submit a biologics license application to the U.S. Food and Drug Administration for ozekibart following the registrational study in chondrosarcoma.

For INBRX‑106, the company has disclosed a Phase 2/3 randomized trial in combination with pembrolizumab in first‑line unresectable or metastatic HNSCC, and a Phase 1/2 trial in checkpoint inhibitor refractory or relapsed NSCLC, with endpoints such as overall response rate, disease control rate, duration of response, progression‑free survival, and safety.

Financial reporting and emerging growth status

Inhibrx Biosciences’ SEC filings and earnings press releases describe it as an emerging growth company under applicable U.S. securities regulations. The company reports research and development expenses, general and administrative expenses, other income and expense, and net income or loss, and explains that, because the spin‑off was accounted for as a reverse spin‑off, its financial statements for periods prior to the spin‑off are the historical financial statements of the former parent, Inhibrx, Inc. These disclosures provide context for how investors may interpret historical financial performance in light of the corporate restructuring and asset sale to Sanofi S.A.

Summary

Overall, Inhibrx Biosciences, Inc. presents itself, through its public disclosures, as a clinical‑stage biopharmaceutical company with a focus on oncology and rare diseases, built around proprietary protein engineering platforms and multivalent biologic formats. Its current clinical pipeline centers on ozekibart (INBRX‑109), a DR5 agonist antibody, and INBRX‑106, an OX40‑targeting sdAb‑based therapeutic candidate, both being evaluated in multiple solid tumor indications. The company’s history is closely linked to the restructuring of Inhibrx, Inc., the sale of the INBRX‑101 program to Sanofi S.A., and the distribution of Inhibrx Biosciences shares to the former parent’s shareholders.